CD274 and non-small cell lung carcinoma: Kaplan–Meier curves of OS in two NSCLC anti‐PD‐1/PD‐L1 cohorts (GSE161537: p = 0.0011; GSE135222: p = 0.072) showed that the low‐risk subgroup had a better prognosis which indicated that the low‐risk subgroup may benefit from the anti‐PD‐1/PD‐L1 immunotherapy (Figure 7c,d).